| abstract |
An antibody having the ability to bind Claudin 6 (CLDN6) for use in a method of treating or preventing cancer comprising inhibiting and / or killing cancer stem cells by administering the antibody having the ability to bind CLDN6 to a cancer patient and by the administration of a chemotherapy, in which the antibody and chemotherapy are administered in synergistically effective amounts, in which the antibody is capable of mediating the death of cells expressing CLDN6 by ADCC and / or CDC and comprises a heavy chain variable region (VH) comprising an amino acid sequence represented by SEQ ID NO: 5 and a light chain variable region (VL) comprising an amino acid sequence represented by SEQ ID NO: 4, and in wherein the chemotherapy comprises an agent selected from the group consisting of carboplatin, gemcitabine, paclitaxel, and cisplatin. |